Surgery Partners, Inc. SGRY
26.58 USD -0.08 (-0.30%)
At closeNov 12, 2026, 4:00 PM EST
26.58 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
26.56 Day range 26.81
11.41 52-week range 27.23
- YTD
- +72.04%
- 1 year
- +67.59%
News
benzinga.com TD Cowen Maintains Hold on Surgery Partners, Raises Price Target to $25 TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Hold and raises the price target from $23.5 to $25.
globenewswire.com SGRY Securities Notice: Surgery Partners Shareholders are Notified to Contact BFA Law about its Investigation into the $23.50 per Share Take-Private Merger NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Surgery Partners, Inc. (NASDAQ:…
benzinga.com RBC Capital Maintains Sector Perform on Surgery Partners, Raises Price Target to $25 RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Sector Perform and raises the price target from $23.5 to $25.
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), ARRAY Technologies, Inc. (NASDAQ – ARRY), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC) BALA CYNWYD, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
businesswire.com SHAREHOLDER BUYOUT ALERT: Kaskela Law LLC Announces Investigation into Proposed Buyout of Surgery Partners, Inc. (SGRY) Shareholders at $23.50 Per Share – Fair Price or Insufficiently Low? PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law announces that it has launched an investigation into the fairness of the proposed buyout of Surgery Partners, Inc. (NASDAQ: SGRY) shareholders to determine…
zacks.com Surgery Partners (SGRY) Beats Q3 Earnings Estimates Surgery Partners (SGRY) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago.
benzinga.com Surgery Partners Q3 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $815.300M Miss $825.648M Estimate Surgery Partners (NASDAQ:SGRY) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of…
globenewswire.com Surgery Partners, Inc. Announces Third Quarter 2026 Results BRENTWOOD, Tenn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today…
benzinga.com HealthSpan Partners Raises Merger Consideration To $25 Per Share For Surgery Partners Surgery Partners, Inc. (NASDAQ: SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, and HealthSpan Partners, a contractual affiliate and supporting
businesswire.com Surgery Partners and HealthSpan Partners Announce Amended Merger Agreement, Following Receipt of Unsolicited Proposal BRENTWOOD, Tenn. & CINCINNATI--(BUSINESS WIRE)--Surgery Partners, Inc. (NASDAQ: SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, and HealthSpan…
globenewswire.com SGRY Deal Alert: Surgery Partners $23.50 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Surgery Partners, Inc. (NASDAQ:…
globenewswire.com SGRY Investigation Reminder: Surgery Partners Shareholders Notified of Investigation into $23.50 per Share Merger – Contact BFA Law NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Surgery Partners, Inc. (NASDAQ:…
benzinga.com UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5 UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Surgery Partners Surges as $5.7 Billion Deal Takes Company Private The Surgery Partners deal values the company at $5.7 billion, offering public shareholders $23.50 per share in cash.
benzinga.com Crude Oil Edges Lower; Chicago Fed Activity Index Rises In September U.S. stocks climbed Monday: Nasdaq +0.99%, S&P 500 +0.75%, led by tech; Surgery Partners and Xtend AI surged, while Brazil-linked stocks fell.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.
benzinga.com HealthSpan Partners Agrees To Acquire Surgery Partners For ~$5.7B In Cash HealthSpan Partners, a contractual affiliate and supporting organization of U.S.-based Bon Secours Mercy Health ("BSMH"), and Surgery Partners, Inc. (NASDAQ:SGRY), a leading short-stay surgical…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
benzinga.com Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
benzinga.com RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.- benzinga.com TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.
benzinga.com Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday Analysts raised price targets for Meta, IREN, Coinbase, Roblox and others; IREN and Coinbase were upgraded, while other ratings held steady.
benzinga.com JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15 JP Morgan analyst Benjamin Rossi maintains Surgery Partners (NASDAQ:SGRY) with a Neutral and raises the price target from $14 to $15.- benzinga.com TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19 TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.
benzinga.com RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19 RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $20 to $19.- benzinga.com Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $18 price target.
- benzinga.com Surgery Partners Q2 Adj. EPS $0.10 Beats $0.06 Estimate, Sales $848.900M Beat $830.366M Estimate Surgery Partners (NASDAQ:SGRY) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 66.67 percent. This is a 41.18 percent decrease over earnings of…
- benzinga.com Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.
benzinga.com Surgery Partners Monetizes Idaho Assets As It Chases Faster Growth Surgery Partners rises after agreeing to sell Idaho Falls hospital stakes for $795 million while reaffirming its 2026 outlook- benzinga.com Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.
- benzinga.com Surgery Partners To Sell Ownership Interests In Mountain View Hospital And Idaho Falls Community Hospital To Intermountain Health; Deal Values Combined Idaho Falls Facilities At ~$1.15B, Total Consideration To Surgery Partners ~$795M Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced it, along with its existing partner Intermountain
benzinga.com Surgery Partners Q1 2026 Earnings Call Transcript - benzinga.com Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.411B Est 2026 GuidanceFull year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million
- benzinga.com Surgery Partners Q1 Adj. EPS $(0.03) Beats $(0.12) Estimate, Sales $810.900M Beat $797.892M Estimate Surgery Partners (NASDAQ:SGRY) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. This is a 175 percent decrease over earnings of $0.04…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Ortelius Urges Surgery Partners Overhaul After Underperformance, Calls For Hospital Divestitures, Board Refresh, And Management Change Surgery Board and Management Team Have Presided Over the Vast Destruction of Value and Must Be Held AccountableLetter Outlines Multiple Paths to Building and Unlocking Intrinsic Value for…
- benzinga.com TD Cowen Maintains Buy on Surgery Partners, Lowers Price Target to $20 TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $28 to $20.
benzinga.com Analyst Expectations For Surgery Partners's Future 
benzinga.com UBS Maintains Buy on Surgery Partners, Lowers Price Target to $21 UBS analyst A.J. Rice maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $29 to $21.- benzinga.com Mizuho Maintains Outperform on Surgery Partners, Lowers Price Target to $17 Mizuho analyst Ann Hynes maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $19 to $17.
- benzinga.com RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $20 RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $31 to $20.
- benzinga.com Barclays Maintains Equal-Weight on Surgery Partners, Lowers Price Target to $14 Barclays analyst Andrew Mok maintains Surgery Partners (NASDAQ:SGRY) with a Equal-Weight and lowers the price target from $18 to $14.
benzinga.com MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue of $695.07M, and Q1 guidance below estimates.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Surgery Partners Stock Hits 52-Week Low - Here's Why Surgery Partners (NASDAQ: SGRY) shares drop in premarket as company reports lower than expected earnings and sets cautious 2026 outlook.
benzinga.com Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quar- benzinga.com Surgery Partners Authorizes A New Share Repurchase Program That Permits The Repurchase Of Up To $200M Of The Company's Common Stock. Share Repurchase ProgramOn February 26, 2026, the Board of Directors of the Company authorized a new share repurchase program that permits the repurchase of up to $200 million of the Company's common…
benzinga.com Surgery Partners Q4 Earnings Assessment - benzinga.com Surgery Partners Sees FY2026 Sales $3.350B-$3.450B vs $3.559B Est Surgery Partners (NASDAQ:SGRY) sees FY2026 sales of $3.350 billion-$3.450 billion vs $3.559 billion analyst estimate.